Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Blood

Volumn 119, Issue 17, 2012, Pages 4083-4090

  Warlick, Erica ^a   Ahn, Kwang Woo ^b   Pedersen, Tanya L ^c   Artz, Andrew ^d   De Lima, Marcos ^e   Pulsipher, Michael ^f   Akpek, Gorgun ^g   Aljurf, Mahmoud ^h   Cahn, Jean Yves ⁱ   Cairo, Mitchell ^j   Chen, Yi Bin ^k   Cooper, Brenda ^l   Deol, Abhinav ^m   Giralt, Sergio ⁿ   Gupta, Vikas ^o   Khoury, H Jean ^p   Kohrt, Holbrook ^q   Lazarus, Hillard M ^l   Lewis, Ian ^r   Olsson, Richard ^s   Pidala, Joseph ^t   Savani, Bipin N ^u   Seftel, Matthew ^v   Socié, Gerard ^w   Tallman, Martin ⁿ   Ustun, Celaettin ^a   Vij, Ravi ^x   Vindeløv, Lars ^y   Weisdorf, Daniel ^a   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f Division of Hematology   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

ⁱ HÔPITAL MICHALLON   (France)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m WAYNE STATE UNIVERSITY   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o PRINCESS MARGARET HOSPITAL   (Canada)

^p EMORY UNIVERSITY HOSPITAL   (United States)

^q STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^r ROYAL ADELAIDE HOSPITAL   (Australia)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^u VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^v UNIVERSITY OF MANITOBA   (Canada)

^w SAINT LOUIS HOSPITAL   (France)

^x BARNES JEWISH HOSPITAL   (United States)

^y Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; IMATINIB; INTERFERON; MELPHALAN; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIBLING; T CELL DEPLETION; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE BODY RADIATION;

EID: 84860338610     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-409763     Document Type: Article

References (22)

1. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99(6):1971-1977. (Pubitemid 34525477)
2. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronicphase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108(5):1478-1484. (Pubitemid 44316111)
3. Hochhaus A, O'Brien SG, Guilhot F, et al. Sixyear follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
5. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24): 2251-2259.
6. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008;14(7):748-758. (Pubitemid 351773151)
7. Giralt S, Logan B, Rizzo D, et al. Reducedintensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program. Biol Blood Marrow Transplant. 2007; 13(7):844-852. (Pubitemid 46902440)
8. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15(12):1628-1633.
9. Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus- malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000; 111(1):18-29.
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15(6):825-828.
11. Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-4249.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV Blood. 2010;115(10):1880-1885.
14. Hochhaus A, Müller MC, Radich J, et al. Dasatinibassociated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 2009;23(9): 1628-1633.
15. le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results [published online ahead of print, November 11, 2011]. Leukemia. doi:10.1038/leu.2011.323.
16. Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinibintolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer. 2012;118(1):118-126.
17. Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leuk Lymphoma. 2010;51(4):583-591.
18. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3):232-238.
19. Jabbour E, Cortes J, Santos FP, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011;117(3):3641-3647.
20. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108(4):1421-1423. (Pubitemid 44232047)
21. Velev N, Cortes J, Champlin R, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010;116(15):3631-3637.
22. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118(20):5697-5700.